These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35635603)

  • 21. The role of experiential knowledge within attitudes towards genetic carrier screening: A comparison of people with and without experience of spinal muscular atrophy.
    Boardman FK; Young PJ; Warren O; Griffiths FE
    Health Expect; 2018 Feb; 21(1):201-211. PubMed ID: 28703871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Participants' perspectives on safety monitoring in clinical trials.
    Flynn KE; Kramer JM; Dombeck CB; Weinfurt KP
    Clin Trials; 2013 Aug; 10(4):552-9. PubMed ID: 23644503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review on Spinal Muscular Atrophy: Awareness, Knowledge, and Attitudes.
    Moultrie RR; Kish-Doto J; Peay H; Lewis MA
    J Genet Couns; 2016 Oct; 25(5):892-900. PubMed ID: 27084745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey.
    Belter L; Cruz R; Jarecki J
    Orphanet J Rare Dis; 2020 Aug; 15(1):217. PubMed ID: 32838797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient and caregiver motivators and barriers to eczema clinical trial participation: Analysis of survey data.
    Jacobson ME; Thibau IJ; Baghoomian W; Latour E; Kastala A; Loiselle AR; Simpson EL; Begolka WS
    Skin Health Dis; 2024 Oct; 4(5):e259. PubMed ID: 39355725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
    Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
    HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "I have SMA, SMA doesn't have me": a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA.
    Mazzella A; Curry M; Belter L; Cruz R; Jarecki J
    Orphanet J Rare Dis; 2021 Feb; 16(1):96. PubMed ID: 33618755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient, Relative and Staff Experiences of Clinical Trial Participation in Neurooncology: "Maybe You Can Also Show the Positive, No Matter How It Ends".
    Thallner R; Gumbinger C; Hohmann A; Wick A; Wick W; Busetto L
    Cancer Manag Res; 2024; 16():663-676. PubMed ID: 38919873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The AMBER care bundle for hospital inpatients with uncertain recovery nearing the end of life: the ImproveCare feasibility cluster RCT.
    Koffman J; Yorganci E; Murtagh F; Yi D; Gao W; Barclay S; Pickles A; Higginson I; Johnson H; Wilson R; Bailey S; Ewart C; Evans C
    Health Technol Assess; 2019 Oct; 23(55):1-150. PubMed ID: 31594555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual health promotion in people with severe mental illness: the RESPECT feasibility RCT.
    Hughes E; Mitchell N; Gascoyne S; Moe-Byrne T; Edmondson A; Coleman E; Millett L; Ali S; Dare C; Hewitt C; Johnson S; Llewellyn C; Mercer C; Nolan F; Walker C; Watson J
    Health Technol Assess; 2019 Dec; 23(65):1-136. PubMed ID: 31854292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Perceived Benefit or Burden of Research Participation With Participants' Withdrawal From Cancer Clinical Trials.
    Ulrich CM; Ratcliffe SJ; Zhou Q; Huang L; Hochheimer C; Gordon T; Knafl K; Miller V; Naylor MD; Schapira MM; Richmond TS; Grady C; Mao JJ
    JAMA Netw Open; 2022 Nov; 5(11):e2244412. PubMed ID: 36449287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do psychiatrists understand research-related experiences, attitudes, and motivations of schizophrenia study participants?
    Warner TD; Roberts LW; Nguyen K
    Compr Psychiatry; 2003; 44(3):227-33. PubMed ID: 12764711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006282. PubMed ID: 22513940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.
    Belter L; Jarecki J; Reyna SP; Cruz R; Jones CC; Schroth M; O'Toole CM; O'Brien S; Hall SA; Johnson NB; Paradis AD
    J Neuromuscul Dis; 2021; 8(1):109-123. PubMed ID: 33104036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
    Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
    HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying Opportunities to Provide Family-centered Care for Families With Children With Type 1 Spinal Muscular Atrophy.
    Murrell DV; Crawford CA; Jackson CT; Lotze TE; Wiemann CM
    J Pediatr Nurs; 2018; 43():111-119. PubMed ID: 30266528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect Benefits in HIV Cure Clinical Research: A Qualitative Analysis.
    Gilbertson A; Kelly EP; Rennie S; Henderson G; Kuruc J; Tucker JD
    AIDS Res Hum Retroviruses; 2019 Jan; 35(1):100-107. PubMed ID: 30009625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention.
    Acheson LS; Clay S; McKetin R; Lintzeris N; Dunlop A; Brett J; Christmass M; Rodgers C; Shoptaw S; Farrell M; Ezard N; Siefried KJ
    Int J Drug Policy; 2024 Apr; 126():104383. PubMed ID: 38479162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy.
    Ramos-Platt L; Elman L; Shieh PB
    Int J Gen Med; 2022; 15():7341-7353. PubMed ID: 36157294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.